Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 7Non-Muscle Invasive Bladder Neoplasms 5Multiple Myeloma 4Glioma 4Carcinoma, Transitional Cell 4Prostatic Neoplasms 3Neoplasms 3Wilms Tumor 2Urothelial Cancer 2Rhabdoid Tumor 2Ovarian Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Esophageal Neoplasms 2Ependymoma 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Acrocephalosyndactylia 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1

Interventions

Gemcitabine 13pembrolizumab 9Specimen Handling 9enfortumab vedotin 8Cisplatin 8Magnetic Resonance Spectroscopy 7avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Immunoglobulin G 3Disulfides 3Biopsy 3eribulin 2cabozantinib 2Standard of Care 2Ramucirumab 2Radiotherapy 2Platinum 2Nephroureterectomy 2Ipilimumab 2Doxorubicin 2Docetaxel 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tremelimumab 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × erdafitinib × Clear all
NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡